To assess the ability of NTP to modulate surface CD47 on cancerous cells, we used three different cancer cell types: glioblastoma (U87), head and neck cancer squamous cell carcinoma (SC263), and melanoma (A375). This evidence concerns the gene CD47 and melanoma.